No Data
In the first quarter, Yaokang Bio (688046.SH) reported a Net income of 29.9803 million yuan, a year-on-year increase of 1.7%.
On April 26, Gelonghui reported that Yaokang Biological (688046.SH) released its quarterly report, achieving a total operating revenue of 0.171 billion yuan in the first quarter of 2025, a year-on-year increase of 8.76%; net income attributable to shareholders of the parent company was 29.9803 million yuan, a year-on-year increase of 1.7%; and the basic EPS was 0.07 yuan.
Yakkang Biotech\'s 2025 First Quarter Report
Yakkang Biotech 2024 Annual Report
Summary of Yakkang Biotech\'s 2024 Annual Report
GemPharmatech Significantly Expands U.S. Capabilities With New San Diego Biotech Hub Facility
About 0.206 billion restricted shares of Yaokang Biology (688046.SH) will be listed and circulated on April 25.
YaoKang Biology (688046.SH) released an announcement that the restricted shares for listing and circulation are part of the company's initial public offering...
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking